Xeris Biopharma (XERS) News Today

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) has a supportive analyst update, with HC Wainwright raising several earnings forecasts and maintaining a Buy rating and $18 price target. The short-interest report is internally inconsistent, so it does not provide a reliable new signal on the stock.

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to $0.14 from $0.04, FY2027 to $0.13 from $0.11, and FY2030 to $1.03 from $0.92. The firm kept its Buy rating and $18 target, a positive signal about its earnings outlook.
• Positive Sentiment: Other recent coverage includes a “Moderate Buy” consensus rating, an upgrade from Wall Street Zen, and Oppenheimer reiterating “Outperform.” Xeris Biopharma Stock Rated Moderate Buy Xeris Biopharma Upgraded at Wall Street Zen Oppenheimer Reiterates Outperform Rating
• Neutral Sentiment: The short-interest item describes a “large increase” but reports total short interest of zero shares. That contradiction makes the figure difficult to interpret and not a dependable catalyst.
• Neutral Sentiment: Analyst views are not unanimous: Piper Sandler reiterated a Neutral rating, and a separate headline characterized HC Wainwright’s earnings outlook as weaker. The specific figures provided, however, show HC Wainwright raising estimates. Piper Sandler Reiterates Neutral Rating HC Wainwright Expects Weaker Earnings